Singapore, November 8, 2024 – DKSH, a leading market expansion service provider for companies seeking to grow their business in Asia and beyond, and Osteopore Limited, an Australian-Singaporean regenerative medicine company and global leader in 3D-printed biomimetic and bioresorbable implants, announce the signing of an exclusive multi-year distribution agreement to distribute Osteopore’s off-the-shelf orthopaedic products in Singapore.
Osteopore’s High Tibial Osteotomy (HTO) product is the centrepiece of the company’s orthopaedic expansion into Singapore. HTO or knee preservation surgeries have doubled in the space of a year – from 50 cases in 2020 to approximately 100 cases in 2021 – according to Singapore General Hospital (SGH). More than 10% of adults in Singapore are impacted by the degenerative joint condition of knee osteoarthritis (KO). This condition is prevalent amongst 40-to-60-year-olds. Knee preservation surgeries have the highest potential for success with this demographic, as they seek to relieve symptoms and delay the need for more invasive surgeries like Total Knee Replacement (TKR)1. Clinical performance data shows accelerated bone union with the Osteopore HTO product when compared to allogeneic fillers2.
Commenting on Osteopore’s promising exclusive distribution agreement with DKSH, Osteopore CEO, Dr Lim Yujing, said: “Partnering with a company which boasts the channel access, resources and experience of DKSH, is a significant opportunity to commercialise our products in a meaningful and sustainable way. Early clinical results for HTO provide partners like DKSH with the confidence to launch a quality product, and we look forward to growing this market segment collaboratively with DKSH.”
Reuben Ong, Vice President, Business Unit Healthcare, DKSH Singapore, said: “We are thrilled to embark on this partnership with the Osteopore Team for the Orthopaedic products, combining our strengths and expertise to drive innovation and deliver greater benefits to the patient. Together, we’re setting a new standard in our industry, creating opportunities that push boundaries and empower growth. This collaboration isn’t just about mutual success—it’s about creating a meaningful impact for the communities we serve and building a future where we can achieve and contribute more, together. At DKSH Healthcare, we believe that if innovation is the heart of health care, then connectivity is the lifeblood. The lifeblood that brings amazing new treatments, to the people that need them the most. DKSH Healthcare’s holistic capabilities in becoming a truly end-to-end strategic partner of choice in connecting the entire healthcare ecosystem and connecting Healthcare Companies to patients to ultimately achieve better healthcare for all.
